An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

January 23, 2014

Primary Completion Date

January 15, 2016

Study Completion Date

June 14, 2017

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

ASP8273

Oral administration

Trial Locations (14)

Site: 4, Fukuoka

Site: 9, Fukuoka

Site: 8, Miyagi

Site: 7, Okayama

Site: 3, Osaka

Site: 6, Osaka

Site: 2, Shizuoka

Site: 1, Tokyo

Site: 5, Tokyo

Site: 10, Seoul

Site: 11, Seoul

Site: 12, Seoul

Site: 13, Taipei

Site: 14, Taipei